201 related articles for article (PubMed ID: 38063879)
1. The COVID-19 inflammation and high mortality mechanism trigger.
Stróż S; Kosiorek P; Stasiak-Barmuta A
Immunogenetics; 2024 Feb; 76(1):15-25. PubMed ID: 38063879
[TBL] [Abstract][Full Text] [Related]
2. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
3. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
[TBL] [Abstract][Full Text] [Related]
5. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
6. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma.
Geng J; Chen L; Yuan Y; Wang K; Wang Y; Qin C; Wu G; Chen R; Zhang Z; Wei D; Du P; Zhang J; Lin P; Zhang K; Deng Y; Xu K; Liu J; Sun X; Guo T; Yang X; Wu J; Jiang J; Li L; Zhang K; Wang Z; Zhang J; Yan Q; Zhu H; Zheng Z; Miao J; Fu X; Yang F; Chen X; Tang H; Zhang Y; Shi Y; Zhu Y; Pei Z; Huo F; Liang X; Wang Y; Wang Q; Xie W; Li Y; Shi M; Bian H; Zhu P; Chen ZN
Signal Transduct Target Ther; 2021 Sep; 6(1):347. PubMed ID: 34564690
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Gong W; Parkkila S; Wu X; Aspatwar A
Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
[TBL] [Abstract][Full Text] [Related]
8. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation.
Fu L; Gilham D; Stotz SC; Sarsons CD; Rakai BD; Tsujikawa LM; Wasiak S; Johansson JO; Sweeney M; Wong NCW; Kulikowski E
Int Immunopharmacol; 2023 Apr; 117():109929. PubMed ID: 36857935
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
Noor R; Shareen S; Billah M
Bull Natl Res Cent; 2022; 46(1):96. PubMed ID: 35431535
[TBL] [Abstract][Full Text] [Related]
10. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
11. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
[TBL] [Abstract][Full Text] [Related]
14. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness.
Tulimilli SV; Dallavalasa S; Basavaraju CG; Kumar Rao V; Chikkahonnaiah P; Madhunapantula SV; Veeranna RP
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298616
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
Zinatizadeh MR; Zarandi PK; Zinatizadeh M; Yousefi MH; Amani J; Rezaei N
Biomed Pharmacother; 2022 Feb; 146():112527. PubMed ID: 34906769
[TBL] [Abstract][Full Text] [Related]
16. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
17. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
[TBL] [Abstract][Full Text] [Related]
18. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
19. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
20. Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases.
Nayak B; Lal G; Kumar S; Das CJ; Saraya A; Shalimar
Front Cell Infect Microbiol; 2021; 11():753249. PubMed ID: 34760721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
